Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 16 (4), 429-436

The Safety of Treatment Options Available for Gout

Affiliations
Review

The Safety of Treatment Options Available for Gout

Naomi Schlesinger. Expert Opin Drug Saf.

Abstract

Gout is the most common inflammatory arthritis in humans. Gout treatment includes rapid initiation of anti-inflammatory medications for acute attacks and chronically treating with urate lowering drugs as well as chronic anti-inflammatory prophylaxis. Areas covered: This review aims to provide an overview and discussion of the safety concerns of current treatment options available for gout. Expert opinion: Gout is a curable disease with appropriate treatment. The advent of new therapies provides encouraging opportunities to improve gout management. However, clinicians should be aware of some of the safety concerns of medications used to treat acute and chronic gout. When prescribing medications for gout one has to be mindful of the presence of comorbidities commonly affecting gout patients that may affect drug safety and efficacy, especially in the elderly and in patients treated with multiple drugs. The benefits of gout drugs, usually, outweigh their safety concerns. Studies are needed in gout patients with chronic kidney disease and/or cardiovascular disease, so that escalation of dosing /combination of anti-inflammatory drugs needed to suppress gouty inflammation as well as escalation of dosing/combination of urate lowering drugs needed to achieve target serum urate level will lead to better understanding of gout treatment safety issues.

Keywords: Safety; acute gout; anti-inflammatory drugs; chronic gout; urate lowering drugs; uric acid.

Similar articles

  • New and Pipeline Drugs for Gout
    RT Keenan et al. Curr Rheumatol Rep 18 (6), 32. PMID 27097819. - Review
    Gout is the most common inflammatory arthropathy in the western world. Affecting millions and accounting for lost wages, increased health care costs, and significant disa …
  • Emerging Therapies for Gout
    JA Singh. Expert Opin Emerg Drugs 17 (4), 511-8. PMID 23126250. - Review
    Multiple new treatment approaches have emerged for gout. Several target acute inflammation of gout flares by inhibiting interleukin-1, either with an antibody or with a m …
  • Expert Opinion on Emerging Urate-Lowering Therapies
    LK Stamp et al. Expert Opin Emerg Drugs 23 (3), 201-209. PMID 30244605. - Review
    There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editori …
  • Evaluation and Treatment of Gout as a Chronic Disease
    F Perez-Ruiz et al. Adv Ther 29 (11), 935-46. PMID 23104464. - Review
    Gout is a disease caused by deposition of monosodium urate crystals in tissues. One of the limitations for successful treatment of gout is to consider it as an intermitte …
  • Canakinumab in Gout
    N Schlesinger. Expert Opin Biol Ther 12 (9), 1265-75. PMID 22784099. - Review
    Canakinumab has been found to be superior to triamcinolone acetonide in acute gout and to colchicine in gout attack prophylaxis in reducing pain and risk of new gout atta …
See all similar articles

Cited by 1 PubMed Central articles

MeSH terms

LinkOut - more resources

Feedback